Relapsing Remitting Multiple Sclerosis Clinical Trials

11 recruiting

Frequently Asked Questions

Common questions about Relapsing Remitting Multiple Sclerosis clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 111 of 11 trials

Recruiting
Not Applicable

The SetPoint System as a Pro-Remyelination Therapy for Relapsing-Remitting Multiple Sclerosis: A Pilot Study

Relapsing Remitting Multiple Sclerosis
SetPoint Medical Corporation60 enrolled3 locationsNCT06796504
Recruiting
Phase 3

RItuximab Versus Ocrelizumab in Relapsing-remitting Multiple Sclerosis.

Multiple SclerosisRelapsing Remitting Multiple Sclerosis
Rennes University Hospital386 enrolled23 locationsNCT05758831
Recruiting
Not Applicable

Functional Outcomes From Diets in Multiple Sclerosis

Relapsing Remitting Multiple SclerosisSecondary Progressive Multiple Sclerosis
University of Alabama at Birmingham100 enrolled2 locationsNCT05327322
Recruiting

Study to Evaluate the Usability and Value of Integrated Digital Solutions in Medical Care of Participants With Multiple Sclerosis

Relapsing Remitting Multiple Sclerosis
Hoffmann-La Roche500 enrolled5 locationsNCT05949580
Recruiting
Phase 3

Best Available Therapy Versus Autologous Hematopoietic Stem Cell Transplant for Multiple Sclerosis (BEAT-MS)

Relapsing Multiple SclerosisRelapsing Remitting Multiple SclerosisSecondary Progressive Multiple Sclerosis
National Institute of Allergy and Infectious Diseases (NIAID)156 enrolled22 locationsNCT04047628
Recruiting

Understanding the 'Durable Effect' Concept of B-cell Modulating Therapies

Relapsing Remitting Multiple Sclerosis
Heinrich-Heine University, Duesseldorf100 enrolled1 locationNCT06586177
Recruiting
Phase 1

SIZOMUS Safety of Ixazomib Targeting Plasma Cells in Multiple Sclerosis

Relapsing Remitting Multiple SclerosisPrimary Progressive Multiple SclerosisSecondary Progressive Multiple Sclerosis
Queen Mary University of London72 enrolled1 locationNCT03783416
Recruiting

Exploratory Study on the Timing of Multiple Sclerosis (MS) Symptoms

Relapsing Remitting Multiple Sclerosis
University of Louisville80 enrolled1 locationNCT00919217
Recruiting

Rituximab and Ocrelizumab in Serum With Multiple Sclerosis

Relapsing Remitting Multiple Sclerosis
Haukeland University Hospital60 enrolled1 locationNCT06663111
Recruiting
Phase 3

A Study to Compare Efficacy, Pharmacokinetics, Pharmacodynamics and Safety of CT-P53 and Ocrevus in Patients With Relapsing-remitting Multiple Sclerosis

Relapsing Remitting Multiple Sclerosis
Celltrion512 enrolled1 locationNCT05906992
Recruiting

Investigation of Subclinical Markers of Multiple Sclerosis

Multiple SclerosisRelapsing Remitting Multiple Sclerosis
University of Split, School of Medicine50 enrolled1 locationNCT04604041